Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$14.16 USD
+0.44 (3.21%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $14.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Takeda Pharmaceutical Co. has a PEG ratio of 0.26 compared to the Medical - Drugs industry's PEG ratio of 1.42.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TAK 14.16 +0.44(3.21%)
Will TAK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Other News for TAK
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
TAK Crosses Below Key Moving Average Level
Takeda (TAK) Reaffirms FY25 Financial Projections
Takeda (TAK) Reports Decline in Q1 Revenue Amid Potential Pipeline Growth
Takeda reports Q1 core EPS 151 yen vs. 176 yen last year